薬剤別の包括的なソリューション
あらゆる段階で分析を効率化して、高い信頼性を確保するように設計された統合ワークフローにより、創薬から品質管理までのプロセスを高速化します。
- 製品
- 製品
- CrossLab サポート商品
- サポート商品
- テクニカルサポート
- HOME
- 分野別ソリューション
- 医薬品・バイオ医薬品の創薬から品質管理までをサポートするワークフロー
低分子医薬品、バイオ医薬品、および未来の革新的新薬の創薬、開発、製造には、多大な取り組みが求められます。ラボは、知識の増加と技術の進歩に最新の知見と技術革新に対応し続ける必要があります。絡み合った科学的およびビジネス上の課題を常に切り抜けていかなければなりません。アジレントは、専門知識、コンプライアンス対応の高度な技術、製造能力（システム、ソフトウェア、消耗品、サービスなど）によりお客様を支援します。また、アジレントの受託開発製造機関（CDMO）サービスは、創薬から市場投入にいたるプロセスの推進にお役立ていただけます。アジレントをパートナーとしてお選びいただくことで、分析を加速し、コストを削減し、さらに二酸化炭素排出量を最小化して、組織の持続可能性目標達成を支援します。アジレントは、創薬の初期段階から商業用 GMP および品質管理まで、バイオ医薬品および医薬品分野でラボの成果を向上させるお手伝いをいたします。
以下のリンクより、詳細をご確認いただけます。
あらゆる段階で分析を効率化して、高い信頼性を確保するように設計された統合ワークフローにより、創薬から品質管理までのプロセスを高速化します。
エキスパートチームがお客様の目標達成をバックアップします。
アジレントのエキスパートサービスとソリューションの包括的なポートフォリオにより、分析を加速し、ワークフローを滞りなく進めることができます。
遺伝子編集、生物製剤、API を網羅する CDMO サービスにより、創薬から市場投入までのプロセスを加速して、プロセス開発、スケールアップ、GMP 製造を実現し、次世代治療薬の開発を推進します。
Drug discovery relies on a broad spectrum of biological, analytical, and preclinical approaches that help scientists understand complex systems, identify opportunities, and accelerate therapeutic innovation. Advances in cellular and molecular techniques, multiomics analyses, and disease‑modeling strategies provide deeper insight into mechanisms of action and biological pathways. Agilent empowers researchers with systems, assays, software, and end‑to‑end expertise to streamline analysis and enhance confidence in decisions.
Understanding the composition and behavior of biological molecules is key to revealing cellular function and dynamics. Researchers often struggle to integrate genomics, proteomics, lipidomics, and metabolomics across multiple platforms—leading to fragmented data and delays in biomarker discovery or target validation. Agilent addresses these challenges with integrated and highly curated end‑to‑end workflows that combine automated sample preparation, sensitive analytics, and intuitive software. The result is streamlined analysis, greater reproducibility, faster discovery, and deeper biological insight.
Breakthroughs in automated imaging, live‑cell monitoring, and flow cytometry are accelerating scientific innovation and shaping the future of therapeutic development. Explore how Agilent cell analysis solutions can deliver richer insights into cellular behavior and reliable, quantitative data you can count on.
Molecular biology and biochemical assays run the gamut from routine ELISAs to microvolume nucleic acid and protein quantification. Microplate reader-based studies, including endpoint and kinetic, single- and multiwavelength formats, are essential experimental tools to measure molecular characteristics and interactions. Agilent BioTek multimode readers have the flexibility and reliability to accommodate a broad range of applications, with excellent performance.
Metabolic pathways shape cell function, disease progression, and therapeutic response. Agilent cell analysis systems enable the direct measurement of dynamic metabolic activity in live cells, revealing the upstream metabolic drivers that inform target identification, mechanism of action, and lead optimization. By delivering sensitive, streamlined metabolic insights, Agilent helps drug developers make more confident decisions earlier in the discovery pipeline.
Mutagenesis and protein engineering are essential tools in modern drug discovery, enabling researchers to modify genes in hundreds or even thousands of ways. This helps uncover distinct biological effects, optimize regulatory sequences, and tailor protein function precisely. To help accelerate these efforts, Agilent offers a comprehensive suite of tools designed to support and streamline mutagenesis and protein engineering workflows, from design through execution.
Identifying gene transcription plays a key role in drug discovery, as changes in gene expression indicates the compound-induced modulation of cellular signaling pathways. Gene expression analysis supports evaluation of mechanisms of action, pharmacokinetics, and toxicity risk. It also provides information supporting potential drug‑repurposing opportunities. Agilent offers proven, automation‑ready solutions for both targeted and large‑scale RNA analysis. From single‑gene studies to whole‑transcriptome profiling, technologies from Agilent provide reliable insight across mRNA, precursor RNA, and noncoding RNA transcripts.
High‑throughput screening powers modern drug discovery by helping researchers rapidly pinpoint promising bioactive compounds from vast chemical libraries. These platforms automate the evaluation of thousands to millions of candidates for biological activity. This dramatically shortens the path from early discovery to viable drug leads, unlocking faster, smarter decisions on what to advance next.
As the FDA, NIH, and European Commission—reduce animal testing with new approach methodologies (NAMs), the industry is moving toward more predictive, human-relevant models that deliver faster results and stronger scientific rigor. Agilent offers 3D cell imaging, real-time metabolic analysis, organ-on-chip metabolomics, in vitro toxicity, ADME, and immunological assays, proven NAM strategies that enhance safety, accelerate timelines, and meet evolving regulatory expectations.
Gain end‑to‑end insight from molecular signatures to whole‑cell functional behavior. Agilent solutions provide faster and more reliable disease research across oncology, cardiovascular biology, neurobiology and beyond.
Modern drug development demands more than speed—it requires connected, high‑quality workflows that translate science into reliable clinical outcomes. Agilent can help across the drug development continuum. Our preclinical and translational enablement workflows integrate innovative technologies to provide deeper insights and de‑risk candidates early. Agilent comprehensive CMC solutions ensure product quality, comparability, and regulatory readiness from candidate through commercialization. Agilent is a proven leader with expertise and a broad technology portfolio including companion diagnostics and precision medicine services. These capabilities offer molecular, biological, and patient‑level insights—enabling smarter decisions and therapies designed to reach the right patients, faster.
Preclinical development and translational enablement generate the integrated scientific and technical evidence needed to advance a candidate toward development readiness. Agilent supports this process with end‑to‑end analytical, bioanalytical, and genomic solutions. These improve data quality and boost confidence, enabling decision‑making across the development process.
As the FDA, NIH, and European Commission reduce animal testing, New approach methodologies (NAMs), are proving to be more predictive, human‑relevant models that deliver faster results and stronger scientific rigor. Agilent helps drug developers implement proven NAM strategies that enhance safety, accelerate timelines, and meet evolving regulatory expectations. Agilent NAM solutions, including 3D cell imaging, real-time metabolic analysis, organ‑on‑chip metabolomics, and drug toxicity solutions that generate quantitative, real‑time data, provide deeper insight into cellular mechanisms and empower the next generation of drug development.
Translational research bridges foundational science and clinical development, revealing drug candidate influence on disease pathways. Agilent solutions for tissue profiling, liquid biopsy, and immune monitoring—including immunoassays and next-generation sequencing—help researchers move promising therapies forward faster with greater confidence.
Address complex ADME, pharmacokinetic, and bioanalytical challenges with confidence using solutions designed to support informed decisions on drug candidate efficacy and safety. Agilent delivers end‑to‑end, regulatory‑ready workflows with the sensitivity, selectivity, and automation needed to quickly and accurately characterize drug behavior—even at low‑nanogram levels.
CMC analytics, quality, and regulatory compliance are the backbone of successful drug development, ensuring every therapy is built on rigorous, reliable data. Gain the clarity and confidence needed to accelerate development while staying ahead of evolving regulatory demands with proven Agilent workflows.
Purification is a critical step in drug development, where isolating a pure target compound from complex mixtures can quickly become a bottleneck. Methods that work at small scale often don’t translate smoothly to production, making yield and purity harder to maintain. Agilent helps overcome these challenges with deep expertise and a broad portfolio of instruments, consumables, and open-access software. Complete workflows that streamline purification for both experts and non-experts—maximizing efficiency, yield, and confidence.
Agilent delivers sensitive impurity detection and end‑to‑end confidence across your critical quality and safety workflows. Our integrated instruments, columns, standards, and informatics help you accelerate method development, simplify validation, and streamline routine testing—without compromising data integrity. With Agilent, you get proven performance, regulatory‑ready workflows, and support that scales from R&D to QC.
Dissolution testing plays a critical role in demonstrating product performance, consistency, and quality throughout the drug lifecycle. Agilent delivers reliable, end‑to‑end solutions for drug dissolution testing designed to support accurate, reproducible results while meeting evolving regulatory requirements. By combining robust instrumentation, trusted consumables, and intelligent software, we can help laboratories streamline analysis to make confident, data‑driven decisions.
Pharmaceutical method development requires robust, accessible analytical approaches that support the drug lifecycle while meeting regulatory standards for accuracy, efficiency, and sustainability. Agilent offers an integrated suite of instruments, consumables, software, and expert services that work seamlessly together to simplify method development from concept to implementation.
USP General Chapter <621> establishes standardized chromatography practices. A recent revision allows for method adjustments that help laboratories modernize legacy USP methods. These updates can significantly shorten analysis time and reduce solvent consumption, supporting cost efficiency and sustainability without compromising analytical confidence. Agilent offers the products, integrated workflows, and expertise to help you maximize benefits from implementing these changes.
Worldwide regulations—including USP methods for small‑molecule drug characterization—set rigorous expectations for confirming structure, purity, potency, and stability at every stage of development. Meeting these requirements often demands multiple analytical techniques. Agilent supports this process with a comprehensive portfolio of instruments, consumables, software, and expertise to help streamline regulatory compliance and ensure confident drug characterization.
Antibodies and proteins introduce unique analytical challenges due to their size, complexity, and susceptibility to interactions. Advancing biotherapeutics through development demands efficiency, supported by streamlined, automated methods, and confidence provided by accurate, reproducible results. Agilent offers an integrated portfolio of solutions designed to address the complexities of protein and antibody analysis, helping you move forward with clarity and speed.
Agilent partners with biopharmaceutical innovators to turn biomarker insights into approved companion diagnostics. With decades of IVD leadership, robust platforms, and global regulatory know‑how, we support your companion diagnostics (CDx) program every step of the way.
Advance your CDx strategy with Agilent end‑to‑end development expertise. Our integrated solutions, regulatory experience, and proven platforms can help you bring targeted therapies to market faster and with greater confidence.
Pharmaceutical manufacturing and quality control demand precision, speed, and unfailing compliance. At Agilent, we help organizations transform complex workflows into smarter, more efficient, and compliance-ready operations—without compromising data integrity or product quality. By combining deep industry expertise with forward-looking innovation, we support manufacturers in meeting evolving regulatory expectations while accelerating time to market. The result is greater confidence throughout every stage of production and QC.
In pharmaceutical manufacturing, in‑process control and production operations are where quality is built, risks are managed, and confidence is earned in real time. Agilent empowers manufacturers to move faster and smarter, so operations can be compliant and efficient.
Process Analytical Technologies (PAT) are reshaping pharma and biopharma manufacturing by enabling real-time monitoring and control that drive Quality by Design (QbD), consistency, and efficiency. With inline insights, PAT helps you optimize faster—catching issues early, reducing waste, and turning process understanding into a competitive edge. The Agilent end‑to‑end portfolio of compliant analytical instruments and software makes it easy to accelerate production and strengthen manufacturing control.
Purification is a critical step in pharmaceutical manufacturing, directly impacting product quality, compliance, and throughput. Complex process streams and strict purity requirements make reliable, efficient purification essential on the manufacturing floor. Agilent delivers the expertise and a robust portfolio of instruments, consumables, and open-access software to simplify purification workflows, reduce risk, and deliver consistent high-quality results.
Pharmaceutical manufacturing depends on rigorous quality control to make every product safe, effective, and compliant with global regulatory standards. Agilent provides complete and proven workflows that deliver accurate, efficient, and compliant, results—so manufacturers can meet regulatory expectations with confidence while continuously improving quality performance.
The Agilent MAM solution delivers the speed, confidence, and clarity needed to accelerate biopharmaceutical characterization and QC. Simultaneously identify, quantify, and monitor CQAs—while detecting product‑ and process‑related impurities in a single workflow. With intuitive, purpose‑built software and high‑resolution mass spectrometry, streamline method transfer from R&D to QC confidently and with ease. Agilent MAM is a complete single‑vendor solution that provides exactly what you need—automated data handling, compliance support, and a clear pass/fail interface that reduces training time and minimizes human error.
Regulatory bodies require verification of starting materials in up to 100% of received containers to ensure pharmaceutical starting material quality and safety. With Agilent advanced Raman spectroscopy, raw materials are rapidly identified through sealed and opaque containers directly in the cGMP warehouse, eliminating sampling, lab testing, and delays. Agilent can accelerate release-to-production by up to 50% with reduced costs, shorter timelines, and a faster, zero-waste approach to material verification.
Verifying the chemical integrity of tablets and capsules before batch release is vital for drug safety, efficacy, and compliance. Manufacturers must confirm content uniformity and monitor polymorphism to ensure consistent API dosage and performance. Agilent delivers a wide range of solutions including industry‑leading chromatography systems and advanced transmission Raman spectroscopy (TRS) for rapid, nondestructive assessment—cutting turnaround from days to minutes, boosting efficiency, and reducing costs.
Agilent delivers sensitive impurity detection and end‑to‑end confidence across your critical quality and safety workflows. Our integrated instruments, columns, standards, and informatics help you accelerate method development, simplify validation, and streamline routine testing—without compromising data integrity. With Agilent, you get proven performance, regulatory‑ready workflows, and support that scales from R&D to QC.
In vitro dissolution testing is critical for proving drug performance and meeting regulatory requirements—but staying compliant across dosage forms can be complex and resource‑intensive. Agilent simplifies compliance with a comprehensive portfolio of manual, semi‑automated, and online dissolution systems designed to meet harmonized pharmacopeial standards. Our solutions support nearly all dosage forms across USP Apparatus 1–7, helping labs produce reliable, audit‑ready results with confidence.
Global regulations, including USP methods, set the standards for ensuring the quality, purity, and consistency of small‑molecule drugs. From structure confirmation to potency and stability, robust analytical testing is required at every stage of development and manufacturing. Agilent supports confident regulatory compliance with a comprehensive portfolio of instruments, consumables, software, and expertise to streamline drug characterization, purity, and impurity analysis.
In regulated labs, compliance is mandatory—but it shouldn’t slow you down. Lengthy validation, complex documentation, and the risk of downtime can drain time and focus, stalling progress. Agilent services and software combine expert consulting, digital tools, and automation to simplify compliance, reduce manual effort, accelerate validation, and keep you confidently aligned with global standards.
Accelerate the path from discovery to market with CDMO services spanning gene editing, biologics, and APIs. These services offer process development, scale-up, and GMP manufacturing to power next-generation therapeutics.
